e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Biomarkers, diagnosis and outcome of respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Role of procalcitonin (PCT) as a marker of severity of community acquired bacterial pneumonia (CABP) compared to PSI, CRB65 abd CURB65
L. Fernandes, A. Mesquita, A. Arora (P.O. Caranzalem, India)
Source:
Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Session:
Biomarkers, diagnosis and outcome of respiratory infections
Session type:
Thematic Poster Session
Number:
2702
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Fernandes, A. Mesquita, A. Arora (P.O. Caranzalem, India). Role of procalcitonin (PCT) as a marker of severity of community acquired bacterial pneumonia (CABP) compared to PSI, CRB65 abd CURB65. Eur Respir J 2013; 42: Suppl. 57, 2702
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Prognostic value of procalcitonin in community-acquired pneumonia
Source: Eur Respir J 2011; 37: 384
Year: 2011
Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015
Performance of CURB-65 and CURB-age in community acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP)
Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment
Year: 2013
Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)?
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Comparison of PSI, A-DROP, CURB-65, CRB-65, and SOAR indices in hospitalized patients with community acquired pneumonia
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
The prognostic value of consecutive C-reactive protein measurements in community acquired pneumonia
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015
Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI)
Source: Annual Congress 2013 –Lung infections: a clinical point of view
Year: 2013
Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Clinical impact of a prediction score for drug-resistance in community-onset pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP)
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015
Correlation of procalcitonin and CRP in community-acquired pneumonia with CRB-65 score and prognosis – results from the German competence network CAPNETZ
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Biomarkers and severity in community-acquired pneumonia (CAP)
Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Year: 2012
C Reactive Protein (CRP), procalcitonin (PCT) and proadrenomedullin (Pro-ADM), as markers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept